7.03
-0.01 (-0.21%)
| Previous Close | 7.04 |
| Open | 7.00 |
| Volume | 535,164 |
| Avg. Volume (3M) | 1,654,536 |
| Market Cap | 408,493,216 |
| Price / Sales | 1.59 |
| Price / Book | 0.570 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 |
| Profit Margin | -240.94% |
| Operating Margin (TTM) | -214.69% |
| Diluted EPS (TTM) | -10.54 |
| Quarterly Revenue Growth (YOY) | 26.20% |
| Total Debt/Equity (MRQ) | 65.32% |
| Current Ratio (MRQ) | 5.62 |
| Operating Cash Flow (TTM) | -319.58 M |
| Levered Free Cash Flow (TTM) | -235.06 M |
| Return on Assets (TTM) | -19.67% |
| Return on Equity (TTM) | -60.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.13 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.57% |
| % Held by Institutions | 81.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ecor1 Capital, Llc | 31 Dec 2024 | 1,743,344 |
| Opaleye Management Inc. | 31 Dec 2024 | 1,200,000 |
| Forbes J M & Co Llp | 31 Dec 2024 | 701,732 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |